Truist Financial Maintains Amgen(AMGN.US) With Hold Rating
Cantor Fitzgerald Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $305
UBS Maintains Amgen(AMGN.US) With Hold Rating, Cuts Target Price to $315
Amgen Analyst Ratings
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $320
Citigroup Adjusts Price Target on Amgen to $300 From $290
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $320 to $389
Cantor Fitzgerald Sticks to Its Hold Rating for Amgen (AMGN)
UBS Adjusts Price Target on Amgen to $315 From $319, Maintains Neutral Rating
RBC Capital Keeps Their Buy Rating on Amgen (AMGN)
HSBC Adjusts Amgen Price Target to $357 From $385, Maintains Buy Rating
HSBC Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $357
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $329
Bernstein Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $350
Amgen Analyst Ratings
Cantor Fitzgerald Maintains Amgen(AMGN.US) With Hold Rating, Raises Target Price to $305
Cantor Fitzgerald Downgrades Amgen(AMGN.US) to Hold Rating
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $329
Goldman Sachs Adjusts Price Target on Amgen to $400 From $408, Maintains Buy Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $350